News &amp; Updates

Among patients receiving immune checkpoint inhibitors (ICIs), those with interstitial lung disease (ILD) have a significantly greater risk of developing checkpoint inhibitor pneumonitis (CIP) and may experience worse outcomes, including recurrence and death, reveals a study.

ILD ups risks of pneumonitis, mortality in patients taking ICIs

Adjunctive soticlestat minimally beneficial in Lennox–Gastaut syndrome

Use of the cholesterol 24-hydroxylase inhibitor soticlestat as adjunctive therapy in patients with Lennox–Gastaut syndrome (LGS) falls short of reducing the frequency of major motor drop (MMD) seizures, according to the results of the phase III SKYWAY trial.

Adjunctive soticlestat minimally beneficial in Lennox–Gastaut syndrome

Can prednisolone be used in place of hydrocortisone in adrenal insufficiency?

13 Apr 2026 by

The use of once-daily, low-dose prednisolone for glucocorticoid replacement in adrenal insufficiency yields substantial improvements in bone turnover and cardiometabolic health markers compared with multiple-dose hydrocortisone, according to the results of a crossover randomized clinical trial.

Can prednisolone be used in place of hydrocortisone in adrenal insufficiency?

More aggressive LDL-C reduction improves cardiac outcomes in ASCVD patients

13 Apr 2026 by

An intensive targeting of low-density lipoprotein cholesterol (LDL-C) level (<55 mg/dL) reduces the risk of cardiovascular events at 3 years in patients with atherosclerotic cardiovascular disease (ASCVD) when compared with conventional targeting (<70 mg/dL), results of the Ez-PAVE trial have shown.

More aggressive LDL-C reduction improves cardiac outcomes in ASCVD patients

13 Apr 2026

LEVI-04 improves knee osteoarthritis outcomes

Treatment with LEVI-04—a p75 neurotrophin receptor (p75NTR) fusion protein that inhibits neurotrophin-3—helps improve pain and function in patients with knee osteoarthritis, as shown in a phase II trial.

LEVI-04 improves knee osteoarthritis outcomes

Perioperative EV plus pembro tied to better outcomes in patients with MIBC

13 Apr 2026 by

Perioperative treatment with enfortumab vedotin and pembrolizumab (EV plus pembro) significantly improves event-free survival (EFS), overall survival (OS), and pathological complete response (pCR) rates in patients with muscle-invasive bladder cancer (MIBC) who are ineligible for cisplatin-based chemotherapy, according to the KEYNOTE-905 trial presented at EAU26.

Perioperative EV plus pembro tied to better outcomes in patients with MIBC

Inhaled mebufotenin shows promise in treatment-resistant depression

Single-day treatment with GH001, a synthetic formulation of inhaled mebufotenin, has been shown to be well tolerated and yield substantial improvements in depressive symptoms in patients with treatment-resistant depression in a phase IIb trial.

Inhaled mebufotenin shows promise in treatment-resistant depression

Vaginal platelet-rich plasma injection boosts sexual function in premenopausal women

Administering platelet-rich plasma injections to the anterior vaginal wall helps improve sexual function in sexually active premenopausal women without severe sexual dysfunction, according to a pilot, single-centre study.

Vaginal platelet-rich plasma injection boosts sexual function in premenopausal women